SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to speculation around potential federal policy changes, including the possibility of the Trump administration reclassifying marijuana, which could ease restrictions and provide tax benefits to cannabis companies. Community members are actively discussing potential entry points, trading strategies around options, and the possible impact on specific companies within the sector. Some caution against hype, noting previous false starts, while others express optimism for substantial gains if rescheduling occurs.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending as traders discuss potential holiday season tailwinds and marketplace expansion. Bullish sentiment is fueled by actionable trade alerts and technical analysis pointing to constructive intraday structure. Community members are also weighing factors like the stock's valuation and potential impact from AI initiatives.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a new partnership with Google involving AI data centers in space, sparking community excitement about the potential for new revenue streams and growth beyond satellite imagery. Bullish sentiment is fueled by analysts raising price targets and institutions increasing their positions, with some viewing the company as undervalued and poised for significant gains. Discussions also revolve around the impact of this development on the broader space sector.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as speculation mounts around potential marijuana rescheduling following reports of a possible executive order. Community discussions revolve around the timing and impact of the announcement, with some expecting significant gains and a short squeeze. The stock is seeing increased interest as investors weigh the potential benefits of eased regulations for the cannabis sector.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potentially disruptive force in the blockchain space, with community members highlighting its impressive transaction speeds and focus on compliance, attracting interest from traditional finance. Discussions emphasize Keeta's role as a complementary infrastructure, not a competitor, to existing blockchains.  Its connections to established entities like Stripe add to its appeal, though some express skepticism, calling it a 'shitcoin'.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos' ATOM crypto is gaining attention due to community discussions surrounding tokenomics changes and comparisons with emerging Layer 1 protocols like Keeta, which boasts impressive transaction speeds and compliance-focused architecture. Community members are weighing ATOM's established interoperability against the potential of newer platforms to disrupt global financial infrastructure, with the token's redesign aimed to improve value accrual. Despite some bearish sentiment, Cosmos' pioneering role in blockchain communication keeps it relevant amid the evolving landscape of Layer 1 solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences Provides Corporate Update Following Recent Financing TuHURA Biosciences Provides Corporate Update Following Recent Financing PR Newswire TAMPA, Fla., Dec. 11, 2025 Company's lead...

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering PR Newswire TAMPA, Fla., Dec. 9, 2025 TAMPA...

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and...

TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

TuHURA Biosciences (NASDAQ:HURA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has earned an average rating of "Buy" from the six analysts that are covering the company, Marketbeat reports. One investment analyst has...

TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results, Beats Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of...

TuHURA Biosciences (NASDAQ:HURA) Price Target Cut to $8.00 by Analysts at Maxim Group

Maxim Group decreased their price target on TuHURA Biosciences from $15.00 to $8.00 and set a "buy" rating for the company in a research note on Friday...

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate...

Shares of Tuhura Biosciences surged 20.2% in after-hours trading on Monday after the company and Kineta, Inc. said shareholders from both firms approved their proposed merger and all related proposals at special meetings held earlier in the day.The stock closed Monday's regular session slightly lower at $2.53, down 0.8%.The merger will combine Tuhura's clinical-stage immuno-oncology platform, including its Phase 3-ready lead asset IFx-2.0, with Kineta's Vista-blocking antibody KVA12123 and a preclinical CD27-targeted therapy.The merged company aims to address primary and acquired resistance to current cancer immunotherapies.Tuhura stockholders approved key measures, including increasing authorized shares to 200 million and reincorporating the company in Delaware.&nbsp;Kineta stockholders also approved the merger terms at a separate special meeting.The transaction is expected to close soon, subject to the fulfillment or waiver of remaining conditions.&nbsp;Tuhura is planning to initiate a randomized Phase 3 trial of IFx-2.0 in combination with Keytruda (pembrolizumab) as first-line therapy for advanced or metastatic Merkel Cell Carcinoma.Kineta's Vista therapy, KVA12123, had previously entered Phase 1/2 trials for solid tumors but was paused in 2024 amid a corporate restructuring that included job cuts to reduce expenses and preserve cash.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user said Tuhura could trade above $10 and reach valuations higher than $15.&nbsp;<stembedurl>https://stocktwits.com/Aburose/message/618740816</stembedurl>Another user noted that the stock had consistently moved higher near the close in recent sessions.<stembedurl>https://stocktwits.com/LifesGood/message/618742837</stembedurl>Tuhura’s stock has declined 38.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Tuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug Pipeline

The merger brings together two biotech firms aiming to tackle immune resistance in cancer, with plans to advance programs targeting Merkel Cell Carcinoma.

Equity

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

Current Price	$1.03
Prev Close	$1.04
Open	$1.07
Dividend Yield	0.00%
50-Day Moving Average	$2.15
Beta	0.41
Avg. Volume	189,973.53
PE Ratio	-1.58

52-Week High	$5.50
52-Week Low	$0.972
Market Capitalization	$53.05M
EPS (Annual)	-$1.21
Price to Book	3.18
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

HURA
TuHURA Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HURA News

HURATuHURA Biosciences Inc.